A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce

Scientific Reports
June 16, 2021

Regular PCR testing of nasopharyngeal swabs from symptomatic individuals for SARS-CoV-2 virus has become the established method by which health services are managing the COVID-19 pandemic. Businesses such as AstraZeneca have also prioritised voluntary asymptomatic testing to keep workplaces safe and maintain supply of essential medicines to patients. We describe the development of an internal automated SARS-CoV-2 testing programme including the transformative introduction of saliva as an alternative sample type.

Genedata helped AstraZeneca to rapidly implement a workflow for analyzing qPCR data using Genedata Screener, including integration with plate management systems.